These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 33986743)

  • 1. Identification, Validation, and Utilization of Immune Cells in Pancreatic Ductal Adenocarcinoma Based on Marker Genes.
    de Koning W; Latifi D; Li Y; van Eijck CHJ; Stubbs AP; Mustafa DAM
    Front Immunol; 2021; 12():649061. PubMed ID: 33986743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Immune Microenvironment on the Prognosis of Pancreatic Ductal Adenocarcinoma Based on Multi-Omics Analysis.
    Yang B; Zhou M; Wu Y; Ma Y; Tan Q; Yuan W; Ma J
    Front Immunol; 2021; 12():769047. PubMed ID: 34777388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
    Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
    Front Immunol; 2021; 12():690056. PubMed ID: 34335594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Key Prognostic Biomarker and Its Correlation with Immune Infiltrates in Pancreatic Ductal Adenocarcinoma.
    Luan H; Zhang C; Zhang T; He Y; Su Y; Zhou L
    Dis Markers; 2020; 2020():8825997. PubMed ID: 32934754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Stratification Based on HIF-1 Signaling for Evaluating Hypoxic Status and Immune Infiltration in Pancreatic Ductal Adenocarcinomas.
    Zhuang H; Wang S; Chen B; Zhang Z; Ma Z; Li Z; Liu C; Zhou Z; Gong Y; Huang S; Hou B; Chen Y; Zhang C
    Front Immunol; 2021; 12():790661. PubMed ID: 34925373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating Immunological Biomarkers: Prognosis of Pancreatic Cancer Patients Reflected by the Immune System.
    van der Sijde F; Mustafa DAM; Vietsch EE; Katsikis PD; van Eijck CHJ
    Pancreas; 2021 Aug; 50(7):933-941. PubMed ID: 34643608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
    Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
    Front Immunol; 2021; 12():648917. PubMed ID: 33777046
    [No Abstract]   [Full Text] [Related]  

  • 8. Unraveling pancreatic ductal adenocarcinoma immune prognostic signature through a naive B cell gene set.
    Zhang S; Ta N; Zhang S; Li S; Zhu X; Kong L; Gong X; Guo M; Liu Y
    Cancer Lett; 2024 Jul; 594():216981. PubMed ID: 38795761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
    Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
    Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological Classification of Pancreatic Carcinomas to Identify Immune Index and Provide a Strategy for Patient Stratification.
    Chen Y; Chen D; Wang Q; Xu Y; Huang X; Haglund F; Su H
    Front Immunol; 2021; 12():719105. PubMed ID: 35111149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma.
    George B; Kudryashova O; Kravets A; Thalji S; Malarkannan S; Kurzrock R; Chernyavskaya E; Gusakova M; Kravchenko D; Tychinin D; Savin E; Alekseeva L; Butusova A; Bagaev A; Shin N; Brown JH; Sethi I; Wang D; Taylor B; McFall T; Kamgar M; Hall WA; Erickson B; Christians KK; Evans DB; Tsai S
    Gastroenterology; 2024 May; 166(5):859-871.e3. PubMed ID: 38280684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel lactylation-related signature to predict prognosis for pancreatic adenocarcinoma.
    Peng T; Sun F; Yang JC; Cai MH; Huai MX; Pan JX; Zhang FY; Xu LM
    World J Gastroenterol; 2024 May; 30(19):2575-2602. PubMed ID: 38817665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
    Zhao L; Zhao H; Yan H
    BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining single-cell and bulk RNA sequencing, NK cell marker genes reveal a prognostic and immune status in pancreatic ductal adenocarcinoma.
    Ouyang Y; Shen R; Chu L; Fu C; Hu W; Huang H; Zhang Z; Jiang M; Chen X
    Sci Rep; 2024 Jul; 14(1):15037. PubMed ID: 38951569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions.
    Lin W; Noel P; Borazanci EH; Lee J; Amini A; Han IW; Heo JS; Jameson GS; Fraser C; Steinbach M; Woo Y; Fong Y; Cridebring D; Von Hoff DD; Park JO; Han H
    Genome Med; 2020 Sep; 12(1):80. PubMed ID: 32988401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological Gene Signature Associated With the Tumor Microenvironment of Pancreatic Cancer After Neoadjuvant Chemotherapy.
    Hane Y; Tsuchikawa T; Nakamura T; Hatanaka KC; Saito T; Tanaka K; Nakanishi Y; Asano T; Noji T; Okamura K; Shichinohe T; Yokota I; Hatanaka Y; Hirano S
    Pancreas; 2020 Oct; 49(9):1240-1245. PubMed ID: 32898010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrating tertiary lymphoid structure-associated genes into computational models to evaluate prognostication and immune infiltration in pancreatic cancer.
    Ma Y; Li X; Zhang J; Zhao X; Lu Y; Shen G; Wang G; Liu H; Hao J
    J Leukoc Biol; 2024 Sep; 116(3):589-600. PubMed ID: 38484172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and Verification of the Hypoxia- and Immune-Associated Prognostic Signature for Pancreatic Ductal Adenocarcinoma.
    Chen D; Huang H; Zang L; Gao W; Zhu H; Yu X
    Front Immunol; 2021; 12():728062. PubMed ID: 34691034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 15-Gene Immune, Stromal, and Proliferation Gene Signature that Significantly Associates with Poor Survival in Patients with Pancreatic Ductal Adenocarcinoma.
    Kandimalla R; Tomihara H; Banwait JK; Yamamura K; Singh G; Baba H; Goel A
    Clin Cancer Res; 2020 Jul; 26(14):3641-3648. PubMed ID: 32234757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.